{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T09:22:47Z","timestamp":1789118567511,"version":"build-2803163510"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Ketogenic diet therapy (KDT) is an evidence-based treatment for refractory epilepsy, particularly in children. Strict adherence to carbohydrate restriction is essential to maintain ketosis, yet many medications contain excipients that can disrupt this balance. Pharmacists play a crucial role in evaluating and adjusting medication regimens for patients on KDT, but limited transparency regarding excipient content often makes this process inefficient and inconsistent. Although some regional databases exist, no systematic and comprehensive resources have been developed for broader use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>This study aimed to systematically classify pharmaceutical excipients and label all medications marketed in the Netherlands according to their compatibility with KDT (\u201cKetoproof\u201d status) using a transparent, reproducible framework that can serve as the foundation for safer prescribing and international standardization.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>A retrospective cross-sectional database analysis was conducted using data from the Dutch G-Standaard (June 2023\u2013March 2024), a national pharmaceutical reference database used in the Netherlands. All excipients authorized in medications marketed in the Netherlands were extracted and classified based on chemical composition, metabolic fate, and administration route. Excipients were assigned a Ketoproof status through a structured decision flowchart, expert consensus, and quality control review. Finally, pharmaceutical products were labeled by cross-referencing their excipient profiles against the classified dataset.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 1047 excipients were identified. Of these, 778 (74%) were successfully classified: 590 (56%) as Ketoproof and 188 (18%) as non-Ketoproof. The remaining 269 (26%) were unclassified. Excipients requiring expert consensus included polyols and sugar alcohols, organic acids, and coloring and flavoring agents, which were carefully assessed for clinical relevance. Among 28,721 pharmaceutical products analyzed, 41% (n\u2009=\u200911,781) were labeled as Ketoproof. The full dataset was integrated into KetoMed, a web-based tool designed to support healthcare professionals in reviewing medications for patients on KDT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study presents the first systematic classification of pharmaceutical excipients for KDT compatibility. The transparent, evidence-informed framework enables structured labeling of medications and supports safer prescribing for patients undergoing KDT. Broader adoption and international collaboration are recommended to establish consensus on excipient classification, enhance regulatory transparency, and integrate Ketoproof labeling into clinical decision-support systems to optimize ketogenic therapy management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11096-026-02156-6","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T13:21:14Z","timestamp":1777987274000},"page":"1850-1857","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Ketoproof? A systematic classification of pharmaceutical excipients for ketogenic diet therapy"],"prefix":"10.1007","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3873-2202","authenticated-orcid":false,"given":"Samir","family":"El Abdouni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5622-668X","authenticated-orcid":false,"given":"Manon G.","family":"den Uil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1218-5644","authenticated-orcid":false,"given":"Zikrullah","family":"Kafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2816-5161","authenticated-orcid":false,"given":"Tatiana Soares","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3245-0471","authenticated-orcid":false,"given":"Elles J. T. M.","family":"van der Louw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2137-5525","authenticated-orcid":false,"given":"Elisabeth J.","family":"Ruijgrok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3448-7665","authenticated-orcid":false,"given":"A. Laura","family":"Nijstad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,5]]},"reference":[{"key":"2156_CR1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2022.5648","author":"N Devi","year":"2023","unstructured":"Devi N, Madaan P, Kandoth N, et al. Efficacy and safety of dietary therapies for childhood drug-resistant epilepsy: a systematic review and network meta-analysis. JAMA Pediatr. 2023. https:\/\/doi.org\/10.1001\/jamapediatrics.2022.5648.","journal-title":"JAMA Pediatr"},{"key":"2156_CR2","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/zxaf036","author":"CY Yen","year":"2025","unstructured":"Yen CY, Kronisch L, Whitley K, et al. Prescribing errors in hospitalized patients on the ketogenic diet. Am J Health Syst Pharm. 2025. https:\/\/doi.org\/10.1093\/ajhp\/zxaf036.","journal-title":"Am J Health Syst Pharm"},{"key":"2156_CR3","doi-asserted-by":"publisher","DOI":"10.1080\/1028415x.2019.1627769","author":"M Barzegar","year":"2021","unstructured":"Barzegar M, Afghan M, Tarmahi V, et al. Ketogenic diet: overview, types, and possible anti-seizure mechanisms. Nutr Neurosci. 2021. https:\/\/doi.org\/10.1080\/1028415x.2019.1627769.","journal-title":"Nutr Neurosci"},{"key":"2156_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpn.2016.07.009","author":"E van der Louw","year":"2016","unstructured":"van der Louw E, van den Hurk D, Neal E, et al. Ketogenic diet guidelines for infants with refractory epilepsy. Eur J Paediatr Neurol. 2016. https:\/\/doi.org\/10.1016\/j.ejpn.2016.07.009.","journal-title":"Eur J Paediatr Neurol"},{"key":"2156_CR5","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-020-01013-4","author":"YE Nisse","year":"2020","unstructured":"Nisse YE, Robert S, Menetre S, et al. Ketogenic diet: a pharmaceutical guide for the management of drug therapy in the pediatric population. Int J Clin Pharm. 2020. https:\/\/doi.org\/10.1007\/s11096-020-01013-4.","journal-title":"Int J Clin Pharm"},{"key":"2156_CR6","doi-asserted-by":"publisher","DOI":"10.1017\/s0317167100001542","author":"D Lebel","year":"2001","unstructured":"Lebel D, Morin C, Laberge M, et al. The carbohydrate and caloric content of concomitant medications for children with epilepsy on the ketogenic diet. Can J Neurol Sci. 2001. https:\/\/doi.org\/10.1017\/s0317167100001542.","journal-title":"Can J Neurol Sci"},{"key":"2156_CR7","doi-asserted-by":"publisher","DOI":"10.1002\/epi4.12225","author":"EH Kossoff","year":"2018","unstructured":"Kossoff EH, Zupec-Kania BA, Auvin S, et al. Optimal clinical management of children receiving dietary therapies for epilepsy: updated recommendations of the International Ketogenic Diet Study Group. Epilepsia Open. 2018. https:\/\/doi.org\/10.1002\/epi4.12225.","journal-title":"Epilepsia Open"},{"key":"2156_CR8","doi-asserted-by":"publisher","DOI":"10.1542\/peds.97.4.506","author":"TJ Feldstein","year":"1996","unstructured":"Feldstein TJ. Carbohydrate and alcohol content of 200 oral liquid medications for use in patients receiving ketogenic diets. Pediatrics. 1996. https:\/\/doi.org\/10.1542\/peds.97.4.506.","journal-title":"Pediatrics"},{"key":"2156_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-8223(01)00021-9","author":"B McGhee","year":"2001","unstructured":"McGhee B, Katyal N. Avoid unnecessary drug-related carbohydrates for patients consuming the ketogenic diet. J Am Diet Assoc. 2001. https:\/\/doi.org\/10.1016\/s0002-8223(01)00021-9.","journal-title":"J Am Diet Assoc"},{"key":"2156_CR10","doi-asserted-by":"publisher","DOI":"10.1177\/0883073819831179","author":"CA Haney","year":"2019","unstructured":"Haney CA, Charpentier A, Turner Z, et al. A proof-of-principle, case-control study to compensate for potential carbohydrates in liquid antiseizure drugs in children on the ketogenic diet. J Child Neurol. 2019. https:\/\/doi.org\/10.1177\/0883073819831179.","journal-title":"J Child Neurol"},{"key":"2156_CR11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2008.01824.x","author":"B Zupec-Kania","year":"2008","unstructured":"Zupec-Kania B. KetoCalculator: a web-based calculator for the ketogenic diet. Epilepsia. 2008. https:\/\/doi.org\/10.1111\/j.1528-1167.2008.01824.x.","journal-title":"Epilepsia"},{"key":"2156_CR12","doi-asserted-by":"publisher","unstructured":"Martin Prado S, Pozas Del Rio M, Canedo Villarroya E, et al.  Controlling carbohydrate content in antiepileptic medications for children on a ketogenic diet. Nutr Hosp. 2022; https:\/\/doi.org\/10.20960\/nh.04036","DOI":"10.20960\/nh.04036"},{"key":"2156_CR13","unstructured":"Keto Diet Calculator. https:\/\/ketodietcalculator.org\/. Accessed 16 Oct 2025"},{"key":"2156_CR14","doi-asserted-by":"publisher","unstructured":"Mart\u00edn Prado S, Pozas Del R\u00edo M, Ca\u00f1edo Villarroya E, , et al. Controlling carbohydrate content in antiepileptic medications for children on a ketogenic diet. Nutr Hosp. 2022; https:\/\/doi.org\/10.20960\/nh.04036","DOI":"10.20960\/nh.04036"},{"key":"2156_CR15","unstructured":"Z-Index. Over de G-standaard. https:\/\/www.z-index.nl\/over-de-g-standaard. Accessed 16 Oct 2025"},{"key":"2156_CR16","unstructured":"Information NCfB. PubChem Compound Summary for CID 1030, Propylene Glycol. https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Propylene-Glycol. Accessed 11 June 2025"},{"key":"2156_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/ani10091526","author":"F Zhang","year":"2020","unstructured":"Zhang F, Nan X, Wang H, et al. Effects of Propylene Glycol on negative energy balance of postpartum dairy cows. Animals. 2020. https:\/\/doi.org\/10.3390\/ani10091526.","journal-title":"Animals"},{"key":"2156_CR18","unstructured":"Singh R, Randhawa SS, Randhawa CS. Propylene glycol as a prophylactic agent for prevention of sub clinical ketosis in buffaloes. Pharma Innov J. 2019"},{"key":"2156_CR19","unstructured":"Singh R, Randhawa SNS, Randhawa CS. Propylene glycol as a prophylactic agent for prevention of sub clinical ketosis in buffaloes. Pharma Innov J. 2019"},{"key":"2156_CR20","doi-asserted-by":"publisher","DOI":"10.1172\/JCI106395","author":"A Lefevre","year":"1970","unstructured":"Lefevre A, Adler H, Lieber CS. Effect of ethanol on ketone metabolism. J Clin Invest. 1970. https:\/\/doi.org\/10.1172\/JCI106395.","journal-title":"J Clin Invest"},{"key":"2156_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.mehy.2020.109638","author":"DF Wilson","year":"2020","unstructured":"Wilson DF, Matschinsky FM. Ethanol metabolism: the good, the bad, and the ugly. Med Hypotheses. 2020. https:\/\/doi.org\/10.1016\/j.mehy.2020.109638.","journal-title":"Med Hypotheses"},{"key":"2156_CR22","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvaa045","author":"C Spoke","year":"2020","unstructured":"Spoke C, Malaeb S. A case of hypoglycemia associated with the ketogenic diet and alcohol use. J Endocr Soc. 2020. https:\/\/doi.org\/10.1210\/jendso\/bvaa045.","journal-title":"J Endocr Soc"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-026-02156-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-026-02156-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-026-02156-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T08:57:59Z","timestamp":1789117079000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-026-02156-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,5]]},"references-count":22,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["2156"],"URL":"https:\/\/doi.org\/10.1007\/s11096-026-02156-6","relation":{},"ISSN":["2210-7711"],"issn-type":[{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,5]]},"assertion":[{"value":"26 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflicts of interest.","order":1,"name":"Ethics","label":"Competing interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No ethics approval was required for this study, as it did not involve human participants, patient data, or identifiable personal information.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Permission to reproduce material from other sources","group":{"name":"EthicsHeading","label":"Declarations"}}]}}